Please assess the completion status of the following clinical trial:

Trial Title: Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of neoplastic meningitis secondary to leukemia, lymphoma (including AIDS-related lymphoma), or solid tumor (including primary CNS tumors or carcinomas of unknown primary site), defined by 1 of the following criteria:~  * Cerebral spinal fluid (CSF) cell count \> 5/μL AND evidence of blast cells on cytospin or by cytology (for patients with leukemia or lymphoma)~ * Presence of tumor cells on cytospin or cytology OR unequivocal presence of meningeal disease by MRI (for patients with solid tumor)~* No conventional therapy for neoplastic meningitis exists~  * Patients with CNS leukemia or lymphoma must be refractory to conventional therapy, including radiotherapy (i.e., second or greater relapse)~* Patients with CNS leukemia or lymphoma must have had a negative bone marrow aspiration within the past 2 weeks~* No clinical evidence of obstructive hydrocephalus~* No compartmentalization of CSF flow by radioisotope indium In 111 or technetium Tc 99 DTPA flow study~* No ventriculoperitoneal or ventriculoatrial shunt unless patient is completely shunt-independent~* No impending spinal cord compression or other CNS involvement (e.g., acute visual loss secondary to optic nerve involvement) requiring emergent local radiotherapy~PATIENT CHARACTERISTICS:~Age~* 3 to 21~Performance status~* Lansky 60-100% (≤ 16 years of age) OR~* Karnofsky 60-100% (\> 16 years of age)~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Calcium ≥ 7 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Sodium 125-150 mmol/L~* Magnesium ≥ 0.7 mmol/L~* Must have or be willing to have an intraventricular access device (i.e., Ommaya reservoir)~* No uncontrolled infection~  * HIV-positive patients with AIDS-related lymphomatous meningitis are eligible~* No other significant uncontrolled systemic medical illness that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Recovered from prior biologic therapy or immunotherapy~Chemotherapy~* Recovered from prior chemotherapy~* At least 1 week since prior intra-colony stimulating factory (CSF) chemotherapy (2 weeks for liposomal cytarabine)~* At least 3 weeks since prior systemic chemotherapy for leptomeningeal disease~* Concurrent systemic chemotherapy to control systemic disease or bulk CNS disease allowed provided the systemic chemotherapy is not an investigational agent OR any of the following:~  * High-dose (\> 1 g/m\^2) methotrexate~ * High-dose (\> 1 g/m\^2) cytarabine~ * Fluorouracil~ * Capecitabine~ * Thiotepa~ * Nitrosoureas~ * Topotecan~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* At least 8 weeks since prior craniospinal radiotherapy and recovered~* No concurrent CNS radiotherapy~  * Concurrent radiotherapy to extra-CNS sites (e.g., painful bone metastases not in the craniospinal axis) allowed~Surgery~* Not specified~Other~* More than 2 weeks since prior and no other concurrent investigational agents~* No other concurrent intra-CSF or systemic therapy for leptomeningeal disease

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues